This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Vaccitech Doses 1st Patient in HBV002, a Phase 1b/2a Clinical Trial of VTP300 immunotherapeutic candidate for Chronic HBV

Vaccitech Doses 1st Patient in HBV002, a Phase 1b/2a Clinical Trial of VTP300 immunotherapeutic candidate for Chronic HBV

01 Feb 2021

Oxford, UK – 1st February 2021 – Vaccitech Ltd, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the dosing of the first patient in HBV002. HBV002 is a Phase 1b/2a clinical trial designed to evaluate the safety and preliminary efficacy of VTP-300 both with and without a low-dose... Read more

Mobile laboratories use LamPORE COVID-19 test, UK Government LamPORE evaluation report shows high accuracy

Mobile laboratories use LamPORE COVID-19 test, UK Government LamPORE evaluation report shows high accuracy

29 Jan 2021

Mobile COVID-19 testing laboratories containing Oxford Nanopore’s LamPORE test are now being deployed in a pilot programme, to support testing efforts, including in remote locations. There are four mobile LamPORE units, currently located in Aberdeen, Telford, Brent and Newbury — where they are being used to support local testing services. This week the first unit to arrive in Scotland started testing in Aberdeen. The unit will move around the... Read more

Boehringer Ingelheim & Enara Bio enter Strategic Collaboration & Licensing Agreement to discover novel shared antigens for cancer immunotherapies

Boehringer Ingelheim & Enara Bio enter Strategic Collaboration & Licensing Agreement to discover novel shared antigens for cancer immunotherapies

12 Jan 2021

Ingelheim, Germany and Oxford and London, UK, January 12th, 2021 – Boehringer Ingelheim and Enara Bio, today announced that they have entered into a strategic collaboration and licensing agreement to research and develop novel targeted cancer immunotherapies, leveraging Enara Bio’s Dark Antigen™ discovery platform. This new collaboration combines Boehringer Ingelheim’s approach to tackle cancer through pairing leading science with... Read more

OXGENE introduces SLIM platform for discovery of antibodies against membrane proteins

OXGENE introduces SLIM platform for discovery of antibodies against membrane proteins

12 Jan 2021

Novel self-labelling mammalian display method for identifying antibodies against membrane proteins in their native configuration Paper published in Journal of Biological Chemistry demonstrates compatibility with downstream manufacturing technologies to help accelerate CAR-T or antibody therapeutics development 12 January 2021, Oxford, UK: OXGENE™, a biotechnology company offering integrated discovery and manufacturing... Read more

Immunocore announces closing of $75.0 Million Series C round

Immunocore announces closing of $75.0 Million Series C round

11 Jan 2021

Funding follows positive Phase 3 trial interim analysis data for tebentafusp in patients with metastatic uveal melanoma (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 January 2021) Immunocore, a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More